查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1856586

核医放射性同位素市场（以放射性药物划分）－全球预测，2025-2032年

Nuclear Medicine Radioisotopes Market by Radiopharmaceuticals - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，核医放射性同位素市场规模将达到 364.5 亿美元，复合年增长率为 14.96%。

关键市场统计数据
基准年 2024 119.4亿美元
预计年份：2025年 137.6亿美元
预测年份 2032 364.5亿美元
复合年增长率 (%) 14.96%

本书权威地介绍了临床创新、生产技术和监管变革如何重塑核医放射性同位素生态系统。

受临床创新、生产技术变革和监管重点调整的驱动，核医学放射性同位素领域正经历显着变化。过去，该领域主要集中于诊断成像和少数由发生器生产的同位素，而如今，它正扩展到精准医疗、一体化诊疗路径以及更加分散的生产模式，这些都对传统的供应链提出了挑战。因此，医疗系统、製造商和监管机构等各方相关人员面临新的技术和商业性现实，需要製定明智的策略应对措施。

本文简要回顾了临床实践、生产方法和监管预期方面的系统性变化，这些变化正在重新定义该领域。

过去几年，临床、供应链和法律规范发生了变革性变化，重塑了核子医学放射性同位素的模式。在临床上，将诊断影像与标靶放射治疗紧密结合的治疗模式的快速普及，改变了标准的治疗路径，并对特定的放射性同位素和标记化合物产生了新的需求。同时，分子标靶治疗和放射化学的进步拓展了多种药物的治疗适应症，促使它们得到更广泛的临床评估和应用。

重点关注2025年美国关税将如何重塑采购、供应链策略和区域製造业优先事项。

2025年，美国推出的关税政策调整为依赖跨境供应放射性同位素前驱物、发生器、合成模组和特种耗材的相关人员带来了新的衝击。这种累积影响体现在筹资策略、供应链架构和成本结构等各个面向。依赖进口的企业被迫重新评估其采购策略，许多企业正在加速推动本地生产计划，或在未受关税调整影响的市场寻找替代供应商。

详细的細項分析表明，诊断用PET和SPECT显像剂及治疗方式各自需要不同的技术、临床和商业策略。

細項分析揭示了诊断和治疗性放射性药物的技术、临床和商业性动态。诊断性药物分为PET和SPECT两类，其中PET药物如F-18 FDG已成为常规肿瘤成像工具，而F-18 PSMA因其高特异性和相比其他PSMA示踪剂更易于操作，在前列腺癌分期和復发检测中得到应用。 SPECT药物由于其成本效益高且γ射线发射同位素广泛可用，继续发挥广泛的临床作用。治疗性药物包括胜肽受体放射性核素疗法，该疗法利用生长抑制素受体靶向治疗神经内分泌肿瘤，并依赖于具有良好剂量分布的同位素和配体组合；放射性栓塞疗法，该疗法将高剂量β射线直接输送到肝臟肿瘤；以及放射免疫疗法，该疗法将单克隆抗体与细胞毒性同位素相结合，用于靶向全身治疗。

重点区域观点，着重分析美洲、欧洲、中东和非洲以及亚太地区在招募、製造能力和法规环境方面的差异。

美洲、欧洲、中东和非洲以及亚太地区的地理差异导致了显着不同的应用曲线、监管方式和生产布局。在美洲，一体化的医疗网路和先进的影像基础设施支援新型PET示踪剂和诊疗一体化药物的快速临床应用，同时政策和报销框架也在不断完善，以适应高价值放射治疗药物的需求。相较之下，欧洲、中东和非洲地区既有成熟的医疗中心，也面临物流和监管方面的挑战，泛欧监管协调工作以及各国为确保同位素供应所做的努力都对生产商和临床机构的战略规划产生了影响。

产业领导者为保障供应链、加速临床应用和提升自身能力所采取的策略性企业因应措施和伙伴关係模式

目前，放射性同位素领域的企业策略强调整合价值链、策略伙伴关係以及能力主导的差异化。各公司优先投资于生产技术，例如迴旋加速器网路和自动化合成平台，同时拓展放射化学和临床开发能力。随着各机构寻求降低供应风险、加快治疗速度并产生支持报销和更广泛临床应用的证据，同位素生产商、受託製造厂商以及临床服务提供者之间的合作日益普遍。

产业领导者可以实施的可操作建议，以增强供应链韧性、加速临床检验并有效实现诊疗整合创新成果的商业化。

产业领导者应采取一系列协调一致的行动，以增强供应链韧性，加快临床检验，并从新的诊疗整合模式中获得长期价值。首先，应优先投资于本地生产能力和可行的替代生产途径，以减少对单一进口的依赖。其次，应促进放射化学家、医学物理学家和临床负责人之间的跨学科合作，以完善剂量和安全通讯协定，从而产生可靠的临床证据，改善患者预后并增强支付方的信心。

采用严谨的混合研究途径，结合专家访谈、技术文献综述以及製造和监管流程图绘製。

本分析所依据的研究采用了一种混合方法，旨在整合技术、临床和商业观点。研究人员透过对临床医生、放射药理学家、生产专家和监管顾问进行结构化访谈，收集了主要的定性数据，以了解实践现状、未满足的需求和推广应用障碍。这些见解与二手技术文献、同行评审的临床研究、监管指导文件和公开的临床试验註册资讯进行三角验证，从而全面了解科学和临床趋势。

总结全文，重点在于阐述临床创新、生产现代化和协作策略之间对于未来成功至关重要的相互作用。

摘要：核医放射性同位素处于临床创新、生产现代化和监管完善快速发展的交会点。治疗诊断学的兴起、迴旋加速器产能的扩张以及对更具韧性的供应链的需求，正共同改变放射性药物的研发、生产和交付方式。透过将技术能力与临床计画设计以及积极的监管互动相结合，医疗系统和生产者可以将科学进步转化为更优质的患者照护。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 扩大镓-68产能以满足日益增长的治疗诊断学需求
  • 采用镏-177标靶放射性配体疗法进行前列腺癌的先进影像
  • 钼-99和Technetium-99m放射性同位素供应链恢復计划
  • 利用迴旋加速器生产碘-123以减少核子反应炉的依赖
  • 加速核准新型核医学同位素的监管协调工作
  • 将人工智慧应用于临床工作流程中放射性药物剂量计算的优化
  • 开发铜-64标记的PET示踪剂以提高癌症影像特异性
  • 大型医疗系统在分散式现场RI发电机安装的投资趋势
  • 生技公司和核能设施合作推动同位素创新
  • 利用锕-225和铅-212的α粒子标靶治疗在肿瘤学领域日益受到关注。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 核医放射性同位素市场（以放射性药物划分）

  • 诊断试剂
    • PET药物
      • F 18 FDG
      • F 18 PSMA
    • SPECT显影剂
  • 治疗药物
    • 胜肽受体放射性核种疗法
    • 放射性栓塞
    • 放射免疫疗法

9. 各地区核子医学放射性同位素市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十章 核医放射性同位素市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十一章 各国核医放射性同位素市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十二章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • General Electric Company
    • Cardinal Health, Inc.
    • Lantheus Holdings, Inc.
    • Curium SAS
    • Siemens Healthcare GmbH
    • Eckert & Ziegler Strahlen-und Medizintechnik AG
    • Nordion Inc.
    • IRE NV
    • Bracco Imaging SpA
    • Jubilant Radiopharma Limited
Product Code: MRR-742BD51821D7

The Nuclear Medicine Radioisotopes Market is projected to grow by USD 36.45 billion at a CAGR of 14.96% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 11.94 billion
Estimated Year [2025] USD 13.76 billion
Forecast Year [2032] USD 36.45 billion
CAGR (%) 14.96%

An authoritative introduction explaining how clinical innovation, production technology, and regulatory shifts are reshaping nuclear medicine radioisotope ecosystems

The landscape of nuclear medicine radioisotopes is undergoing a period of substantive change driven by converging clinical innovations, shifts in production technology, and evolving regulatory priorities. Historically centered on diagnostic imaging and a small set of generator-produced isotopes, the field now spans precision therapeutics, integrated diagnostic-therapeutic pathways, and more distributed production models that challenge legacy supply chains. As a result, stakeholders across healthcare systems, manufacturers, and regulators are confronting new technical and commercial realities that require informed strategic responses.

In clinical settings, the expansion of theranostics and targeted radionuclide therapies has redefined disease management for oncology and other specialties, increasing demand for reliable isotopic supply, specialized radiochemistry capabilities, and robust logistics. Concurrently, manufacturing innovations such as expanded cyclotron deployment and alternative Mo-99/Tc-99m production pathways are emerging to mitigate historical bottlenecks. Taken together, these forces are reshaping investment priorities and partnership structures. Therefore, an introduction to this domain must emphasize both the technical specifics of isotope production and the system-level implications for clinical adoption, reimbursement, and cross-industry collaboration.

A concise examination of the systemic transformations in clinical practice, production methods, and regulatory expectations that are redefining the sector

The past several years have revealed transformative shifts that are redefining the nuclear medicine radioisotopes landscape across clinical practice, supply chains, and regulatory frameworks. Clinically, the rapid uptake of theranostic paradigms-where diagnostic imaging tightly couples with targeted radiotherapeutics-has changed standard care pathways and created new demand profiles for specific radioisotopes and labeled compounds. Concurrent advances in molecular targeting and radiochemistry have expanded the therapeutic index for several agents, prompting broader clinical evaluation and adoption.

On the production side, there has been a marked move toward decentralization with greater investment in hospital-based and regional cyclotron capacity, as well as interest in alternative generator and reactor-independent production techniques. These developments are complemented by improvements in automation for synthesis and quality control, which streamline operations and reduce exposure risks. From a regulatory perspective, agencies are refining guidance to accommodate novel radiopharmaceutical manufacturing controls, aseptic processing innovations, and accelerated clinical pathways for high-need indications. Together, these shifts are creating a more resilient yet complex ecosystem that rewards integrated technical capability and agile regulatory engagement.

A focused analysis of how United States tariff measures introduced in 2025 are reshaping procurement, supply chain strategy, and regional manufacturing priorities

In 2025, tariff policy changes instituted by the United States introduced another vector of disruption for stakeholders who depend on cross-border supply of radioisotope precursors, generators, synthesis modules, and specialized consumables. The cumulative impacts are observable across procurement strategies, supply chain architecture, and cost structures. Import-dependent organizations have been prompted to reassess sourcing, with many accelerating local manufacturing projects or seeking alternative suppliers in markets unaffected by tariff adjustments.

Beyond procurement, tariffs have influenced contractual negotiations, inventory management practices, and long-term capital planning. Firms that previously relied on low-cost foreign components are now evaluating vertical integration or strategic partnerships to internalize critical capabilities. At the same time, regulatory and customs complexities have created operational friction that can extend lead times for clinical programs and manufacturing scale-up. As a consequence, industry players are prioritizing supply chain mapping, supplier qualification diversification, and investment in regionalized capacity to mitigate tariff-driven exposure and preserve continuity of care.

Granular segmentation insights revealing how diagnostic PET and SPECT agents and therapeutic modalities each demand distinct technical, clinical, and commercial strategies

Segmentation analysis reveals distinct technical, clinical, and commercial dynamics across diagnostic and therapeutic radiopharmaceuticals. Diagnostic agents split into PET and SPECT categories, with PET agents like F-18 FDG established as routine oncologic imaging tools and F-18 PSMA gaining prominence for prostate cancer staging and recurrence detection because of its superior specificity and logistical handling compared with some alternative PSMA tracers. SPECT agents continue to serve widespread clinical roles where gamma-emitting isotopes remain cost-effective and widely available. Therapeutic agents encompass peptide receptor radionuclide therapy, which leverages somatostatin receptor targeting for neuroendocrine tumors and depends on isotopes and ligands with favorable dosimetry profiles; radioembolization approaches that deliver high-dose beta emitters directly to hepatic tumors; and radioimmunotherapy strategies that combine monoclonal antibodies with cytotoxic isotopes for targeted systemic treatment.

These distinctions carry operational implications for manufacturers and providers. PET workflows require robust radiochemistry, rapid distribution, and regulatory compliance for short-lived isotopes, while therapeutic modalities demand specialized dosimetry, patient selection protocols, and multidisciplinary clinical teams. Consequently, organizations involved in radiopharmaceutical development must align laboratory capabilities, distribution networks, and clinical partnerships to address the unique requirements of each segment and to translate scientific advances into meaningful patient outcomes.

Key regional perspectives showing how adoption, manufacturing capacity, and regulatory environments vary across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Geographic variation drives meaningful differences in adoption curves, regulatory approaches, and manufacturing footprints across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, integrated healthcare networks and advanced imaging infrastructure support rapid clinical adoption of novel PET tracers and theranostic agents, while policy and reimbursement frameworks are evolving to accommodate high-value radiotherapeutics. By contrast, Europe, the Middle East & Africa present a heterogeneous landscape where well-established centers of excellence coexist with regions that face logistical and regulatory hurdles; pan-European regulatory harmonization efforts and national initiatives to secure isotope supply influence strategic planning for producers and clinical sites.

In the Asia-Pacific region, rapid investment in cyclotron capacity, growing clinical trial activity, and increasing domestic manufacturing capabilities are notable trends. Several markets in the region are focusing on expanding local production to reduce import dependency and to address rising clinical demand. Across all regions, differences in reimbursement models, hospital infrastructure, and regulatory timelines necessitate tailored commercialization strategies and local partnerships to achieve sustainable access and scale.

Strategic corporate responses and partnership models that industry leaders are deploying to secure supply chains, accelerate clinical adoption, and differentiate through capabilities

Corporate strategies in the radioisotope domain now emphasize integrated value chains, strategic partnerships, and capability-led differentiation. Firms are prioritizing investments in production technologies, such as cyclotron networks and automated synthesis platforms, while also expanding capabilities in radiochemistry and clinical development. Collaboration between isotope producers, contract development and manufacturing organizations, and clinical providers is increasingly prevalent as organizations seek to de-risk supply, accelerate time to clinic, and build evidence that supports reimbursement and broader clinical adoption.

In addition, companies are diversifying route-to-market approaches by licensing proprietary ligands, forming co-development agreements for theranostic pairs, and pursuing regional manufacturing alliances. Intellectual property management, quality systems harmonization, and regulatory engagement remain central to competitive positioning. Collectively, these strategies reflect a shift from single-product development toward end-to-end solutions that marry isotope supply security with clinical utility and commercial scalability.

Actionable recommendations that industry leaders can implement to strengthen supply resilience, accelerate clinical validation, and commercialize theranostic innovations effectively

Industry leaders should pursue a coordinated set of actions that strengthen supply resilience, accelerate clinical validation, and position organizations to capture long-term value from emerging theranostic paradigms. First, prioritize investment in regional production capacity and validated alternative production pathways to reduce dependency on single-source imports. Second, cultivate multidisciplinary collaborations between radiochemists, medical physicists, and clinical trialists to generate robust clinical evidence and to refine dosing and safety protocols that improve patient outcomes and payer confidence.

Furthermore, organizations should engage proactively with regulators to shape pragmatic pathways for quality assurance, sterility testing, and lot release that reflect the technical realities of short-lived isotopes. Operationally, integrating automation and digital quality controls can reduce turnaround times and enhance reproducibility. Finally, commercial strategies must focus on building payer relationships and demonstrating real-world value through outcomes and health economic evidence, while also developing flexible distribution and inventory models that accommodate the logistical constraints of radiopharmaceuticals.

A rigorous mixed-methods research approach integrating primary expert interviews, technical literature synthesis, and production and regulatory process mapping

The research underpinning this analysis employed a mixed-methods approach designed to integrate technical, clinical, and commercial perspectives. Primary qualitative data were collected through structured interviews with clinicians, radiopharmacists, manufacturing specialists, and regulatory advisors to capture operational realities, unmet needs, and adoption barriers. These insights were triangulated with secondary technical literature, peer-reviewed clinical studies, regulatory guidance documents, and publicly available clinical trial registries to ensure a comprehensive understanding of scientific and clinical trends.

Analytical steps included a systematic mapping of production technologies, a review of manufacturing process controls relevant to radiopharmaceuticals, and an assessment of logistics and cold-chain considerations specific to short-lived isotopes. The methodology emphasized reproducibility by documenting data sources, interview protocols, and analytical assumptions, and by conducting sensitivity checks on qualitative findings. Where applicable, patent landscapes and regulatory filings were examined to validate strategic positioning and to identify potential technology inflection points.

A conclusive synthesis emphasizing the critical interplay of clinical innovation, production modernization, and collaborative strategies for future success

In summary, nuclear medicine radioisotopes occupy a fast-evolving junction of clinical innovation, manufacturing modernization, and regulatory refinement. The rise of theranostics, expansion of cyclotron capacity, and the need for more resilient supply chains are collectively altering how radiopharmaceuticals are developed, produced, and delivered. Healthcare systems and manufacturers that align technical capabilities with clinical program design and proactive regulatory engagement will be best positioned to translate scientific advances into improved patient care.

Moving forward, success will depend on cross-sector collaboration, transparent supply chain strategies, and evidence generation that demonstrates clinical and economic value. By embracing integrated approaches that combine secure isotope production, automated manufacturing processes, and targeted clinical development, stakeholders can mitigate operational risk while accelerating adoption of next-generation diagnostic and therapeutic radiopharmaceuticals.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of gallium-68 production capacity to meet growing theranostics demand
  • 5.2. Adoption of lutetium-177 targeted radioligand therapies for advanced prostate cancer imaging
  • 5.3. Supply chain resilience initiatives for molybdenum-99 and technetium-99m radioisotopes
  • 5.4. Emerging cyclotron-based production of iodine-123 to reduce reactor dependence
  • 5.5. Regulatory harmonization efforts for fast-track approval of novel nuclear medicine isotopes
  • 5.6. Integration of artificial intelligence for optimized radiopharmaceutical dose calculation in clinical workflows
  • 5.7. Development of copper-64 labeled PET tracers for enhanced cancer imaging specificity
  • 5.8. Investment trends in decentralized on-site radioisotope generator installations by major health systems
  • 5.9. Collaborative partnerships between biotech companies and nuclear facilities driving isotope innovation
  • 5.10. Growth of alpha-emitting targeted therapies using actinium-225 and lead-212 in oncology applications

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nuclear Medicine Radioisotopes Market, by Radiopharmaceuticals

  • 8.1. Diagnostic Agents
    • 8.1.1. PET Agents
      • 8.1.1.1. F 18 Fdg
      • 8.1.1.2. F 18 Psma
    • 8.1.2. SPECT Agents
  • 8.2. Therapeutic Agents
    • 8.2.1. Peptide Receptor Radionuclide Therapy
    • 8.2.2. Radioembolization
    • 8.2.3. Radioimmunotherapy

9. Nuclear Medicine Radioisotopes Market, by Region

  • 9.1. Americas
    • 9.1.1. North America
    • 9.1.2. Latin America
  • 9.2. Europe, Middle East & Africa
    • 9.2.1. Europe
    • 9.2.2. Middle East
    • 9.2.3. Africa
  • 9.3. Asia-Pacific

10. Nuclear Medicine Radioisotopes Market, by Group

  • 10.1. ASEAN
  • 10.2. GCC
  • 10.3. European Union
  • 10.4. BRICS
  • 10.5. G7
  • 10.6. NATO

11. Nuclear Medicine Radioisotopes Market, by Country

  • 11.1. United States
  • 11.2. Canada
  • 11.3. Mexico
  • 11.4. Brazil
  • 11.5. United Kingdom
  • 11.6. Germany
  • 11.7. France
  • 11.8. Russia
  • 11.9. Italy
  • 11.10. Spain
  • 11.11. China
  • 11.12. India
  • 11.13. Japan
  • 11.14. Australia
  • 11.15. South Korea

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2024
  • 12.2. FPNV Positioning Matrix, 2024
  • 12.3. Competitive Analysis
    • 12.3.1. General Electric Company
    • 12.3.2. Cardinal Health, Inc.
    • 12.3.3. Lantheus Holdings, Inc.
    • 12.3.4. Curium SAS
    • 12.3.5. Siemens Healthcare GmbH
    • 12.3.6. Eckert & Ziegler Strahlen- und Medizintechnik AG
    • 12.3.7. Nordion Inc.
    • 12.3.8. IRE NV
    • 12.3.9. Bracco Imaging S.p.A.
    • 12.3.10. Jubilant Radiopharma Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 5. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. NUCLEAR MEDICINE RADIOISOTOPES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 22. NUCLEAR MEDICINE RADIOISOTOPES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NUCLEAR MEDICINE RADIOISOTOPES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 FDG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 FDG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 FDG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 FDG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 FDG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 FDG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 PSMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 PSMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 PSMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 PSMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 PSMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 PSMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PEPTIDE RECEPTOR RADIONUCLIDE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PEPTIDE RECEPTOR RADIONUCLIDE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PEPTIDE RECEPTOR RADIONUCLIDE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PEPTIDE RECEPTOR RADIONUCLIDE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PEPTIDE RECEPTOR RADIONUCLIDE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PEPTIDE RECEPTOR RADIONUCLIDE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOEMBOLIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOEMBOLIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOEMBOLIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOEMBOLIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOEMBOLIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOEMBOLIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 70. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 71. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 72. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 73. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 74. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 75. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 77. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 82. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 84. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 86. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 88. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 92. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 94. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 96. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 98. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 109. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 112. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 113. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 114. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 115. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 116. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 117. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 118. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 122. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 124. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 126. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 128. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 129. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 132. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 133. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 134. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 135. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 136. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 137. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 138. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 154. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 155. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 156. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 157. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 158. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 159. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 160. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 161. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 164. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 165. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 166. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 167. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 168. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 169. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 170. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 181. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 184. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 185. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 186. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 187. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 188. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 189. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 190. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 191. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 194. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 195. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 196. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 197. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 198. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 199. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 200. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 201. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 204. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 205. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 206. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 207. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 208. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 209. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 210. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 214. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 215. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 216. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 217. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 218. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 219. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 221. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 222. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 223. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 224. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 225. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 226. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 227. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 228. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 229. MEXICO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 230. MEXICO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 231. MEXICO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 232. MEXICO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 233. MEXICO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 234. MEXICO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 235. MEXICO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 236. MEXICO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 237. BRAZIL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 238. BRAZIL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 239. BRAZIL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 240. BRAZIL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 241. BRAZIL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 242. BRAZIL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 243. BRAZIL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 244. BRAZIL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 253. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 254. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 255. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 256. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 257. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 258. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 259. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 260. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 261. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 262. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 263. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 264. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 265. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 266. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 267. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 268. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 269. RUSSIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 270. RUSSIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 271. RUSSIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 272. RUSSIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 273. RUSSIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 274. RUSSIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 275. RUSSIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 276. RUSSIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 277. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 278. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 279. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 280. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 281. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 282. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 283. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 284. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 285. SPAIN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 286. SPAIN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 287. SPAIN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 288. SPAIN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 289. SPAIN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 290. SPAIN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 291. SPAIN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 292. SPAIN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 293. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 294. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 295. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 296. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 297. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 298. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 299. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 300. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-